Silencing of microRNAs (miRNAs) by promoter CpG island methylation may be an important mechanism in prostate carcinogenesis. To screen for epigenetically silenced miRNAs in prostate cancer (PCa), we treated prostate normal epithelial and carcinoma cells with 5-aza-2 0 -deoxycytidine (AZA) and subsequently examined expression changes of 650 miRNAs by megaplex stemloop reverse transcription --quantitative PCR. After applying a selection strategy, we analyzed the methylation status of CpG islands upstream to a subset of miRNAs by methylation-specific PCR. The CpG islands of miR-18b, miR-132, miR-34b/c, miR148a, miR-450a and miR-542-3p showed methylation patterns congruent with their expression modulations in response to AZA. Methylation analysis of these CpG islands in a panel of 50 human prostate carcinoma specimens and 24 normal controls revealed miR-132 to be methylated in 42% of human cancer cases in a manner positively correlated to total Gleason score and tumor stage. Expression analysis of miR-132 in our tissue panel confirmed its downregulation in methylated tumors. Re-expression of miR-132 in PC3 cells induced cell detachment followed by cell death (anoikis). Two pro-survival proteins---heparin-binding epidermal growth factor and TALIN2---were confirmed as direct targets of miR-132. The results of this study point to miR-132 as a methylation-silenced miRNA with an antimetastatic role in PCa controlling cellular adhesion.
INTRODUCTION
Prostate cancer (PCa) persists as one of the most frequent deathcausing cancers in the Western world. Techniques such as prostate-specific antigen analysis, biopsy and Gleason score have improved the detection and clinical management of the disease, but problems with their accuracy beg for novel approaches to correctly assess the presence of PCa, monitor its progression and predict its outcome. 1 Histone modifications and DNA cytosine methylation of promoter-related CpG islands dominate as epigenetic mechanisms, and engage in normal gene regulation and development. Modification to a cell's normal epigenetic signature leads to disease, and in cancer such changes arise early and consistently across patients. 2, 3 The identification of epigenetic abnormalities offers a promising route for biomarker discovery, and the ability to reverse epigenetic modifications with drugs offers a therapeutic advantage over clinically challenging genetic manipulation. In PCa, various studies have identified tumor-suppressor genes silenced by promoter methylation. 4, 5 Disease-related epigenetic transformations have also been linked to microRNAs (miRNAs). 6 miRNAs may act as oncogenes or tumor suppressors, and contribute to cancer initiation and progression. 7, 8 Deregulated miRNA levels have been observed for PCa with an overall lower expression of the miRNAome. 9 , 10 The discovery of cancer-specific promoter hypermethylation of numerous miRNAs has demonstrated an epigenetic mechanism for aberrant miRNA expression. 11 Many methylation-silenced miRNAs have been identified such as miR-9, miR-34b/c and miR-148a in metastatic carcinomas, 12 and miR-137 and miR-193a in oral cancer. 13 miR-193b and miR-145 have been identified as tumor suppressors silenced by promoter methylation in PCa, 14, 15 but few studies have focused on miRNA epigenetic regulation in this type of carcinoma.
Through a genomic and pharmacological approach, we herein screened for miRNAs silenced by CpG island hypermethylation in PCa. After observing the methylation of a subset of miRNAs in tumor cell lines, we analyzed their status in vivo revealing the methylation silencing of miR-132. Ectopic re-expression of miR-132 downregulated two pro-survival target genes, heparinbinding epidermal growth factor (HB-EGF) and TALIN2, and resulted in anoikis. Finally, miR-132 expression seems related to clinical outcome in a large cohort of patients.
RESULTS AND DISCUSSION
Screening for epigenetically silenced miRNAs in PCa To identify miRNAs potentially methylated in PCa, we treated the cell lines PrEC (normal prostate epithelial cells), LNCaP, DU145 and PC3 (PCa metastases to lymph node, brain and bone, respectively) with the demethyltransferase inhibitor, 5-aza-2 0 -deoxycytidine (AZA), and analyzed the expression of 650 miRNAs by megaplex stemloop reverse transcription --quantitative PCR (RT --qPCR). We then applied a series of selection and elimination criteria represented by the workflow in Supplementary Figure S1 .
AZA increased the expression (minimum two-fold) of 82, 74, 99 and 66 miRNAs in PrEC, LNCaP, DU145 and PC3 cells, respectively. We initially focused on AZA-upregulated miRNAs in the tumorigenic cell lines and used the Ensembl browser to search for CpG islands 10 kb upstream from their pre-miRNA coordinates (same strand miRNAs present within 10 kb of each other were clustered).
Supplementary Table S1 lists the 73 AZA-responsive miRNAs with upstream CpG islands.
As methylation contributes to regular cell function, we treated PrEC with AZA to identify miRNAs with non-cancer-specific methylation. Of the 73 candidate miRNAs in Supplementary Table S1, 11 miRNAs had a similar induction in AZA-treated PrEC and were not considered further.
The subsequent criterion involved the selection of miRNAs with downregulated basal expression in tumor cells with respect to PrEC as methylation implies diminished gene expression. For the 62 miRNAs of interest, 38 exhibited this downregulation at a cut-off of p0.5-fold (Supplementary Tables S1 and S2) .
By Methylation-specific PCR (MSP), we investigated the methylation status of the 20 CpG islands upstream to these Figure 1 . Pharmacological unmasking of methylation-silenced miRNAs in PCa cell lines by miRNAome megaplex stemloop RT--qPCR. (a) Basal miRNA expression levels with respect to PrEC (set to 1). PC3, DU145 and LNCaP were purchased from the American Type Cell Collection (Manassas, VA, USA), whereas normal human prostate epithelial cells were purchased from Lonza (Lonza Walkersville, Walkersville, MD, USA). All cells were cultured as recommended by their vendor. (b) Response to AZA for the seven miRNAs methylated in tumor but not in PrEC (Step 6 in study workflow---Supplementary Figure S1 ; control cells set to 1). Cells were treated for 72 h with 3 mM AZA (Sigma-Aldrich, St Louis, MO, USA) refreshed daily. Total RNA was extracted with the miRneasy mini kit (Qiagen, Hilden, Germany). Whole-genome miRNA profiling and data processing were performed as described previously. 40, 41 Relative units (RU) are shown on the y-axis. (c) MSP agarose gel images of CpG islands upstream to these seven miRNAs in PrEC and the respective tumor cell line responsive to AZA treatment. Genomic DNA was extracted with the QIAamp DNA mini kit (Qiagen) and underwent bisulfite conversion with the Epitect Bisulfite kit (Qiagen). The Ensembl Genome Browser (http:// www.ensembl.org/index.html) was used to search for CpG islands within 10 kb upstream from the candidate mature miRNA. Primers for MSP were designed with MSPPrimer and are listed in Supplementary Table S5 (ref. 42) . MSP reactions on new primers were optimized using methylated (Meth. positive control) and unmethylated (Unmeth. positive control) bisulfite-converted control DNA (Epitect control DNA set; Qiagen). Figure S1 ). Analysis of variance followed by Bonferroni post-hoc test determined statistically significant differences in mean expression values. Table S2. A total of 28 miRNAs were eliminated as candidates as they had either consistently unmethylated CpG islands or methylated islands in PrEC. Figures 1a --c illustrate the basal expression, AZA response and MSP results for the final candidates, miR-132, miR148a, miR-18b, miR-34b/c (clustered), miR-450a/542-3p (clustered), with respect to PrEC. The five CpG islands upstream to these miRNAs were methylated solely in the tumor cells of interest and hence were subsequently analyzed in vivo. The tumor-specific promoter methylation of miR-148a, miR-18b and miR-34b/c in cancers other than prostate has already been described. 12, 16, 17 Recently, miR-542-3p was shown to initiate apoptosis in cancer cells. 18 miR-132's differential expression between normal and tumorous tissues indicates a context-dependent role as either an oncomiR or a tumor suppressor with upregulated expression in lung, 19 breast 20 and tongue carcinomas, 21 and downregulated expression in osteosarcoma 22 and gliomas. 23 A recent report linked miR-132 methylation to pancreatic carcinogenesis. 24 To analyze the clinical relevance of miRNA promoter methylation in PCa, MSP was performed for the final candidates in 74 clinical prostate FFPE specimens: 24 normal prostate samples (12 from cistoprostatectomies and 12 from normal tissues surrounding PCa) and 50 PCa samples from radical prostatectomies (Supplementary Table S3 ). Methylation occurred in 0%, 5% and 13% of cancers for miR-18b, miR-148a and miR-450a/542-3p, respectively. Control cases showed no methylation. For miR-34b/c, we detected methylation in 48% of control and 87% of cancer cases. Here, methylation frequencies differed between the two control groups: cistoprostatecomies had 25% methylation and normal surrounding tissue had 67%. In cases of normal surrounding tissue positive for methylation (8 out of 12), the cancerous counterpart was also positive. The four unmethylated cases were also negative in the paired cancer tissue. This suggests that miR34b/c CpG island methylation does not occur in a tumor-specific manner but may correlate with prostatic tissue alterations such as prostatic intraepithelial neoplasia.
miRNAs and tabulated the results in Supplementary
For miR-132, MSP of the same samples detected methylation frequencies of 8% in control and 42% in cancer (P ¼ 0.002, Fisher's exact test). This specificity furnished the hypothesis of a relationship between miR-132 expression and clinical parameters. miR-132 expression and CpG island methylation correlate with clinical and pathological variables We analyzed the expression of miR-132 in relation to various clinical parameters using the Taylor et al.
25 GSE21032 data set available on the GEO website. miR-132 expression data were available for 111 tumors including 13 metastases. Lower miR-132 levels correlated with higher incidence of metastatic samples, metastatic events and lymph node invasion (Figures 2a and b) . Furthermore, samples with low miR-132 levels had reduced recurrence-free time (Figure 2c) . We also observed a negative correlation of miR-132 expression levels with overall Gleason score (Supplementary Figure S3a) and tumor stage (Supplementary Figure S3b) . Together, this describes a consistent picture of PCa invasiveness and recurrence potential associated with low miR-132 levels.
These results provoked us to scrutinize miR-132's methylation data in our patient cohort, hypothesizing that cancers of higher total Gleason score (X7) and/or pathological stage (XpT3) would have greater frequencies of methylation, as these pathological characteristics correlate positively with tumor aggressiveness and metastatic ability. We found a significant correlation between methylation presence and pathological tumor stage (Figure 2d ; P ¼ 0.03, Fisher --Freeman --Halton exact test), as well as total Gleason score (o7 versus X7; Figure 2e ; P ¼ 0.04, Fisher's exact test). Figure 2f shows a sample MSP result for four representative cases.
The importance of miR-132 in PCa prompted us to verify its expression levels in PC3 and PrEC, as well as in our tissue panel. As shown in Supplementary Figures S2a --c , we used geNorm to identify stable reference genes in both contexts so as to ensure high-quality data. 26 Supplementary Figure S2b shows miR-132's expression in PC3 and PrEC (basal and AZA-responsive) as validated over three biological replicates. RT --qPCR of miR-132 in our tissue panel showed downregulated expression (P ¼ 0.02) in methylated tumor samples only (Figure 2g ).
miR-132 evokes cell death by anoikis, and impedes cell migration and invasion To investigate the biological role of miR-132 in PCa, we reintroduced miR-132 into PC3 cells by transient transfection and confirmed transfection efficiency by RT --qPCR (Supplementary Figure S4a) . miR-132-transfected cells assumed a rounded phenotype and, at 72 h, many cells floated in the medium (Figure 3a) . According to Galluzzi et al. 27 we investigated endstage cell death by two distinct methods---Trypan blue absorption and lactate dehydrogenase (LDH) activity.
Total cell viability by growth curve analysis with Trypan blue assaying revealed a 20% (P ¼ 0.04) and 40% (P ¼ 0.02) decreased viability for miR-132-expressing cells at 96 and 144 h, respectively (Figure 3b ). LDH enzyme activity doubled for miR-132-transfected cells at 96 h (P ¼ 0.03; Figure 3c ).
We discriminated between attached and floating cells in our growth curve analysis. Figure 3d Next, to unravel the underlying death mechanism, we used flow cytometry to quantify the number of live, apoptotic and necrotic cells at 72 and 96 h after transfection by a fluorescein diacetate and propidium iodide assay. 28 At 72 h, the percentage of viable cells did not differ between control and miR-132-transfected cells (Supplementary Figure S4b) . As shown in Figure 3e floating cells died within 24 h of suspension. Several reports have noted adhesion as an imperative factor in PCa bone metastasis, for which the PC3 cell line stands as a model. 29, 30 Indeed, certain therapeutic agents used in advanced PCa treatment induce anoikis and trigger a phenotype in PCa cells similar to that caused by miR-132 (refs. 31 and 32).
HB-EGF and TALIN2 are direct miR-132 targets
The tumor-suppressive function of miR-132 mediated by anoikis implied targets associated with cellular adherence. As shown in Supplementary Table S5 , an analysis of miR-132 expression and KEGG pathway signatures suggests that this miRNA participates in pathways of cell adhesion, tumor initiation and progression.
To remain within the context of our anoikis phenotype, we used the TargetScan5.1 software to search for putative targets implicated in cellular adhesion as described in the literature. HB-EGF mRNA possesses two conserved putative miR-132 target sites in its 3 0 -UTR (untranslated region) (Figure 4a ) and functions pleiotropically as an oncogene, with pivotal roles in survival, cell adhesion, angiogenesis and tumorigenicity. 33 HB-EGF has increased expression in androgen-independent PCa cell lines and contributes to the transition from an androgen-dependent to an androgen-independent state. 34, 35 DNA methylation silences miR-132 in PCa A Formosa et al
In the same way, we identified a conserved putative miR-132 target site in TALIN2's 3 0 -UTR. TALIN proteins connect integrins to the actin cytoskeleton, and consist of the genes TALIN1 and TALIN2, whose different contributions to cellular adherence are not fully described. 36, 37 Interestingly, a recent study underscored TALIN1's role in PCa cellular adhesion and anoikis resistance. 38 To confirm HB-EGF and TALIN2 as direct miR-132 targets, we cloned their 3 0 -UTR sequences downstream to a luciferase reporter gene and transfected the resulting vectors concomitantly with vectors harboring deleted miR-132-binding sites in the presence of premiR-132 or a scrambled sequence. miR-132 caused luciferase activity to decrease in both vectors bearing HB-EGF and TALIN2 3 0 -UTR sequences, with about 70% inhibition for the former and 20% for the latter (Figure 4a) . Deletion of the first conserved miR-132-binding site in HB-EGF's 3 0 -UTR rescued about 40% of luciferase activity, whereas deletion of the second conserved site recovered little luciferase signal, thus identifying the former as the principal miR-132 target sequence. With regard to TALIN2, deletion of miR-132's putative target sequence fully rescued luciferase activity.
We analyzed the mRNA and protein expression of both targets in PC3 cells transfected with a scrambled sequence or premiR-132. PremiR-132 decreased the mRNA levels of both HB-EGF and TALIN2 by about 40% (Figure 4c ), accompanied by a reduction in protein levels as evidenced by western blotting (Figure 4d) .
To investigate the in vivo correlation of miR-132 expression with that of HB-EGF and TALIN2 mRNAs, we turned to the GSE21032 data set. 25 Both targets had profiles of pro-survival genes, where, at a z-score cut-off of ±2, 7.2% and 20.8% of patients had deregulated mRNA levels for HB-EGF and TALIN2, respectively, and 495% of these showed upregulated expression (Supplementary Figure S5) . For both target mRNAs, we found a negative correlation with miR-132 expression in metastatic samples (Figure 4e ), which best resemble the cell line PC3, but this was not statistically significant likely given the sample size (n ¼ 13).
We next analyzed the role of HB-EGF and TALIN2 in proliferation, adherence and migration through gene silencing by RNA interference (Figure 4f ). Figure 4g shows the anti-proliferative effect of HB-EGF knockdown, whereas Figures 4h and i illustrate the anti-adherent and migratory effect of TALIN2 knockdown. The latter result points to TALIN2 as the target protein of greater importance in miR-132's cellular function. However, inhibition of neither HB-EGF nor TALIN2 resulted in the dramatic phenotype observed with miR-132 re-expression, most probably owing to the pleiotropic action of miR-132 on numerous targets, coupled with off-target effects. Indeed, the TargetScan5.1 software lists 283 putative conserved targets for miR-132, and several have predicted roles in PCa and adhesion pathways, as shown by the DIANA mir-Path software 39 tabulated in Supplementary Table S6 . In conclusion, we have described the CpG island methylation silencing of miR-132 in PCa in a manner positively correlated with pathological tumor stage and Gleason score. Moreover, low miR-132 expression seems to signify poorer clinical prognosis. Our results show that, in PCa, miR-132 decreases cellular adhesion and consequently increases cell death, the inverse of which stands as imperative for circulating cells to stick to a foreign organ. Such a role may explain the correlation found here between lower miR-132 levels and increased metastatic ability, and raises concerns regarding current therapeutic strategies: could chemotherapy drugs used to repress tumor invasiveness by increasing cellular adherence give circulating cells a metastatic advantage? 0 -UTRs in a luciferase reporter gene construct leads to decreased relative luciferase activity in the presence of miR-132 in HEK 293E cells 24 h after co-transfection, and deletion of miR-132's binding sites leads to signal recovery. Human 3 0 -UTRs of miR-132 target mRNAs were amplified by PCR from human genomic DNA using the primer pairs reported in Supplementary  Table S5 . PCR fragments were restricted and ligated to a compatible XbaI-linearized pGL3Control vector (Promega, Madison, WI, USA). A total of 2 Â 10 5 HEK 293E cells were seeded in 12-well dishes 24 h before transfection. A 100-ng weight of pGL3 vectors, 0.012 nmoles of scrambled or premiR-132 sequences, and 10 ng of Renilla luciferase pRL-CMV vector (Promega E2261) were co-transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's suggestions. Luciferase assays were performed as described previously. 44 *Po0.05 by one-way repeated-measures analysis of variance and Tukey's HSD post-hoc test. **Po0.01. (c) Relative mRNA levels of HB-EGF and TALIN2 in control (Ctrl) and miR-132-expressing cells at 72 h after transfection as determined by RT --qPCR. Total RNA was retro-transcribed using the InPromII Reverse Transcription System (Promega A3800) according to the manufacturer's recommendations. The 15-ml qPCR reaction consisted of 2 Â SYBR green PCR master mix (Applied Biosystems, Foster City, CA, USA), 10 ng of cDNA and 0.4 mM forward and reverse primers. The geometric mean of B-actin and B2M (primers given in the geNorm kit by Primer design) was used to normalize qPCR data. The cycling conditions followed the manufacturer's recommendations (see Supplementary Table S5 for primer sequences). *Po0.05 as determined by Student's t-test. (d) HB-EGF and TALIN2 protein levels 72 h after transfection as determined by western blotting. Protein extraction, sodium dodecyl sulfate --PAGE and antibody incubations were performed as described previously 44 (anti-HBEGF (Abcam ab16783), 1:125 dilution; anti-TALIN2 (Abcam ab108967), 1:50000 dilution). (e) miR-132 expression correlates negatively with target mRNA expression in metastatic PCa samples. 25 Upper left: Pearson correlation coefficient and associated P-value. (f ) Silencing by RNA interference abolishes the protein expression of HB-EGF and TALIN2 at 72 h after transfection. Small interfering RNA sequences were purchased from Dharmacon (Lafayette, CO, USA) (ON-TARGETplus SMARTpool; cat. no. L-019624-00-005, siHB-EGF; cat. no. L-012909-00-005, siTALIN2) and transfected as described for premiR-132 sequences (see Figure 2a) . (g) Silencing of HB-EGF impedes proliferation, whereas silencing of TALIN2 results in (h) cellular detachment and (i) impaired cell migration (see Figure 3 for protocols). All error bars represent standard deviation of at least three independent experiments. *Po0.05, **Po0.01.
